Arax Advisory Partners’s Definium Therapeutics DFTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$85.2K Buy
2,239
+1,446
+182% +$60.9K ﹤0.01% 2932
2026
Q2
$37.3K Buy
793
+327
+70% +$8.08K ﹤0.01% 3510
2026
Q1
$8.81K Sell
466
-13
-3% -$221 ﹤0.01% 2512
2025
Q4
$6.41K Buy
+479
New +$5.93K ﹤0.01% 2713
2025
Q3
– Sell
-501
Closed -$3.25K – 4050
2025
Q2
$3.25K Buy
501
+237
+90% +$1.56K ﹤0.01% 2391
2025
Q1
$1.54K Sell
264
-12
-4% -$86 ﹤0.01% 2158
2024
Q4
$1.92K Buy
276
+248
+886% +$1.71K ﹤0.01% 2021
2024
Q3
$160 Hold
28
– – ﹤0.01% 2530
2024
Q2
$202 Hold
28
– – ﹤0.01% 2438
2024
Q1
$264 Hold
28
– – ﹤0.01% 1267
2023
Q4
$103 Hold
28
– – ﹤0.01% 1310
2023
Q3
$88 Hold
28
– – ﹤0.01% 1300
2023
Q2
$100 Hold
28
– – ﹤0.01% 1250
2023
Q1
$89 Hold
28
– – ﹤0.01% 1252
2022
Q4
$62 Buy
+28
New +$78 ﹤0.01% 1257
2022
Q1
– Sell
-29
Closed -$1K – 1186
2021
Q4
$1K Buy
29
+3
+12% +$96 ﹤0.01% 1041
2021
Q3
$1K Hold
26
– – ﹤0.01% 921
2021
Q2
$1K Buy
+26
New +$1.36K ﹤0.01% 886

Other funds holding DFTX

Arax Advisory Partners's DFTX Position: Q3 2026 in Review

Arax Advisory Partners increased its Definium Therapeutics (DFTX) stake by 182% in Q3 2026, buying an estimated $60.9K and bringing the position to 2,239 shares worth $85.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2932.

Arax Advisory Partners first reported a position in DFTX in Q2 2021 and has held it in 18 quarters since. 354 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.

  • Arax Advisory Partners held 2,239 shares of Definium Therapeutics worth $85.2K as of Q3 2026.
  • Arax Advisory Partners bought 1,446 Definium Therapeutics shares in Q3 2026, an estimated $60.9K.
  • Definium Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q3 2026, its #2932 holding.
  • Arax Advisory Partners first reported a position in Definium Therapeutics in Q2 2021 and has held it in 18 quarters since.
  • 354 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.

Based on Arax Advisory Partners's 13F filing for Q3 2026, filed 12 Nov 2026.